Ferrocenoyl pyridine arene ruthenium complexes with anticancer properties: synthesis, structure, electrochemistry, and cytotoxicity.
Organometallic ruthenium(II) complexes of general formula [Ru(eta(6)-arene)Cl(2)(NC(5)H(4)OOC-C(5)H(4)FeC(5)H(5))], where arene = C(6)H(6) (1), C(6)H(5)Me (2), p-iPrC(6)H(4)Me (3), and C(6)Me(6) (4), and of general formula [Ru(eta(6)-arene)Cl(2)](2)(NC(5)H(4)OOC-C(5)H(4)FeC(5)H(4)-COOC(5)H(4)N), where arene = p-iPrC(6)H(4)Me (5) and C(6)Me(6) (6), have been synthesized and characterized, the molecular structures of these complexes being confirmed by single-crystal X-ray structure analysis of complex 4 as a representative example. The redox properties and in vitro anticancer activities of complexes 1-6 have been studied. All the compounds are moderately cytotoxic toward the A2780 and A2780cisR (cisplatin-resistant) human ovarian carcinoma cell lines. The diruthenium arene complexes 5 and 6 are about twice as active as their mononuclear analogues 3 and 4. Cyclic voltammetry revealed a good correlation of the RuII/RuIII redox potentials of 1-4 and the number of alkyl substituents in the arene ligand.
Auzias
Mathieu
M
Institut de Chimie, Université de Neuchâtel, Case postale 158, CH-2009 Neuchâtel, Switzerland.
Therrien
Bruno
B
Süss-Fink
Georg
G
Stepnicka
Petr
P
Ang
Wee Han
WH
Dyson
Paul J
PJ
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D018360:Crystallography, X-Ray; D004563:Electrochemistry; D005260:Female; D005296:Ferrous Compounds / Q000737:chemistry*; D006801:Humans; D000075163:Metallocenes; D011725:Pyridines / Q000737:chemistry*; D017975:Ruthenium Compounds / Q000737:chemistry* / Q000494:pharmacology*
D000970:Antineoplastic Agents; D005296:Ferrous Compounds; D000075163:Metallocenes; D011725:Pyridines; D017975:Ruthenium Compounds; C023666:pyridine; C004998:ferrocene